NCT00816361

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	MEDI-573	Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.

Timeline

• Start date: 2009-03-09
• Primary completion: 2012-09-11
• Completion: 2012-09-11
• First posted: 2009-01-01
• Last updated: 2019-03-04
• Results posted: 2019-03-04

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study